ATE382346T1 - Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten - Google Patents

Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten

Info

Publication number
ATE382346T1
ATE382346T1 AT04776158T AT04776158T ATE382346T1 AT E382346 T1 ATE382346 T1 AT E382346T1 AT 04776158 T AT04776158 T AT 04776158T AT 04776158 T AT04776158 T AT 04776158T AT E382346 T1 ATE382346 T1 AT E382346T1
Authority
AT
Austria
Prior art keywords
dose
antimetabolites
combination
treated
antimetabolite
Prior art date
Application number
AT04776158T
Other languages
English (en)
Inventor
Robert Johnson
Yiqing Zhou
Thomas Mueller
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Application granted granted Critical
Publication of ATE382346T1 publication Critical patent/ATE382346T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04776158T 2003-05-30 2004-05-28 Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten ATE382346T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47490603P 2003-05-30 2003-05-30
US10/856,342 US20050020534A1 (en) 2003-05-30 2004-05-27 Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites

Publications (1)

Publication Number Publication Date
ATE382346T1 true ATE382346T1 (de) 2008-01-15

Family

ID=33567529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776158T ATE382346T1 (de) 2003-05-30 2004-05-28 Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten

Country Status (6)

Country Link
US (1) US20050020534A1 (de)
EP (1) EP1631267B1 (de)
AT (1) ATE382346T1 (de)
DE (1) DE602004011051T2 (de)
ES (1) ES2297478T3 (de)
WO (1) WO2005002506A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
RS52642B (sr) * 2004-11-18 2013-06-28 Synta Pharmaceuticals Corp. Jedinjenja triazola koja modulišu aktivnost hsp90
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
JP5118039B2 (ja) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
WO2007041294A2 (en) * 2005-09-29 2007-04-12 The Trustees Of Boston University Methods for sensitizing cancer cells to inhibitors
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
EP2032545A2 (de) * 2006-05-25 2009-03-11 Synta Pharmaceuticals Corporation Verbindungen als modulatoren der hsp90-aktivität und verfahren für ihre identifizierung
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
US8071766B2 (en) * 2008-02-01 2011-12-06 Takeda Pharmaceutical Company Limited HSP90 inhibitors
WO2010033771A2 (en) 2008-09-19 2010-03-25 Trustees Of The University Of Pennsylvania Modulators of hsp70/dnak function and methods of use thereof
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US20140296176A1 (en) * 2011-08-19 2014-10-02 Synta Pharmaceuticals Corp. Combination cancer therapy with an hsp90 inhibitor and an antimetabolite
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2014018862A1 (en) * 2012-07-27 2014-01-30 Corning Incorporated Pharmaceutical compositions comprising a heat shock protein inhibitor and a|purine de novo synthesis inhibitor for treating rheumatoid arthritis or cancer
KR20160015076A (ko) 2014-07-30 2016-02-12 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 Hsp90
KR102394636B1 (ko) * 2015-06-30 2022-05-09 (주)아모레퍼시픽 피부 미백용 조성물 및 피부 미백 효능 물질을 스크리닝하는 방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
DE69329073T2 (de) * 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
EP1140017B9 (de) * 1998-12-22 2005-05-04 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Verabreichungssystem für wasserunlösliche arzneistoffe
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
DZ3223A1 (fr) * 1999-10-19 2001-04-26 Merck & Co Inc Inhibiteurs de tyrosine kinases
US20030215453A1 (en) * 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2002036574A1 (en) * 2000-11-06 2002-05-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Geldanamycin derivatives useful for the treatment of cancer
DE60213386T2 (de) * 2001-03-30 2006-11-23 The United States Of America Represented By The Secretary, Department Of Health And Human Services Geldanamycinderivate zur krebsbehandlung
WO2002089805A2 (en) * 2001-05-03 2002-11-14 Midamerica Neuroscience Research Foundation Use of regularly scheduled high dose intravenous methotrexate therapy
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1420747A4 (de) * 2001-08-06 2010-06-02 Kosan Biosciences Inc Benzochuinonansamycine
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050203174A1 (en) * 2004-03-09 2005-09-15 Kosan Biosciences, Inc. Combination therapies using leptomycin B
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor

Also Published As

Publication number Publication date
US20050020534A1 (en) 2005-01-27
EP1631267B1 (de) 2008-01-02
ES2297478T3 (es) 2008-05-01
DE602004011051T2 (de) 2009-03-26
WO2005002506A2 (en) 2005-01-13
EP1631267A2 (de) 2006-03-08
WO2005002506A3 (en) 2005-09-01
DE602004011051D1 (de) 2008-02-14
EP1631267A4 (de) 2006-07-12

Similar Documents

Publication Publication Date Title
ATE382346T1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
ATE437653T1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
WO2005000211A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
MY169308A (en) Treatment of tnf? related disorders
WO2005000212A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
CY1107484T1 (el) Παραγωγα γκελνταναμυκινης χρησιμοποιουμενα για τη θεραπεια καρκινου
ATE517632T1 (de) Niedrigdosierte verfahren zur behandlung von erkrankungen, bei denen tnf-alpha-aktivität schädlich ist
TW200507833A (en) Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
CY1111565T1 (el) Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
TW200510397A (en) Conjugated complement cascade inhibitors
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
WO2005000214A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
DE60320770D1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
EA200501166A1 (ru) Составы и способы лечения тромбоцитемии
DE602004001134D1 (de) Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties